

Pemazyre (pemigatinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION	
LAST NAME:	FIRST NAME:
PHONE NUMBER:	DATE OF BIRTH:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
PATIENT INSURANCE ID NUMBER:	

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.

Pemazyre (pemigatinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
<input type="checkbox"/> Unresectable, locally advanced cholangiocarcinoma <input type="checkbox"/> Metastatic cholangiocarcinoma <input type="checkbox"/> Relapsed or refractory myeloid/lymphoid neoplasm(s) (MLNs) <input type="checkbox"/> Other diagnosis: _____ ICD-10: _____		
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
Clinical Information: Is this drug being prescribed to this patient as part of a treatment regimen specified within a sponsored clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No Has patient had prior use of a selective FGFR inhibitor(Balversa(erdafitinib))? <input type="checkbox"/> Yes <input type="checkbox"/> No For diagnosis of unresectable, locally advanced or metastatic cholangiocarcinoma, please answer the following: Does patient's cholangiocarcinoma have a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit lab report.</i> Has patient's disease progressed after at least one prior systemic treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> Is patient ambulatory AND capable of self-care? <input type="checkbox"/> Yes <input type="checkbox"/> No For diagnosis of relapsed or refractory myeloid/lymphoid neoplasms(MLNs), please answer the following: Is patient's myeloid/lymphoid neoplasm positive for FGFR1 arrangement? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit lab report.</i> Did patient relapse after stem cell transplant or after disease modifying therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> Was patient not a candidate for stem cell transplantation or for other disease modifying therapies? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> Does patient have graft versus host disease? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> Does patient have an ECOG status 0 to 2? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review? _____ _____		

Pemazyre (pemigatinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201

P.O. Box 64811

St. Paul, MN 55164-0811